The Tata-backed personalised cancer therapy developer has completed a $40m round that increased its funding to $76m altogether.
Mitra Biotech, a US-based medical response analysis technology developer backed by conglomerate Tata, has closed a $40m funding round led by venture capital firm Northpond Ventures.
VC firms Accel and Sequoia Capital, growth capital firm Sands Capital Ventures and investment manager RA Capital Management also joined the round.
Founded in 2010, Mitra is working on a platform, Canscript, that predicts how a patient will react to any given therapy, making it possible to offer personalised treatments.
Michael Rubin, chief…